JMT101 plus afatinib or osimertinib potently inhibit EGFR 20ins in vitro and in vivo
NSCLC
NSCLC
To assess the antitumor activity of JMT101 plus afatinib or osimertinib, common EGFR 20ins in NSCLC, A767_V769dup (insASV), S768_D770dup (insSVD) and N771_H773dup (insNPH), were stably expressed in Ba/F3 cells. Treatment with JMT101 alone from 1 to 200ug/ml had minimal effect on cell viability (Supplementary Fig 